LPA and cardiovascular disorder: Some lipid-lowering agents that are not specific for Lp(a) reduce Lp(a) levels (e.g., niacin, PCSK9 inhibitors, and CETP inhibitors) [108]; however, to date, no randomized controlled trial has demonstrated that the lowering of Lp(a) leads to decreased risk of cardiovascular disease.